Document Detail


Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis.
MedLine Citation:
PMID:  9220059     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
S. boulardii has been investigated in Europe and the US, and preliminary reports indicate that it is safe and effective in conjunction with vancomycin or metronidazole for the treatment of CDC, predominantly in patients who develop recurrence. S. boulardii in combination with vancomycin or metronidazole has not been shown to be more effective than either of these agents alone for treatment of a first episode of CDC. In addition, S. boulardii has not been studied in immunocompromised patients who may be at risk for developing fungemia. Ultimately, large-scale clinical studies are necessary to determine whether S. boulardii should be routinely used to treat patients with recurrent CDC. S. boulardii is currently undergoing Phase III clinical trials for CDC treatment in the US. Clinicians interested in information regarding participation in current studies may contact Biocodex Inc., in Seattle, Washington.
Authors:
J T Eddy; M K Stamatakis; E H Makela
Related Documents :
3147819 - The disposable contact lens: a new concept in extended wear.
19178409 - Atopic dermatitis and allergic reactions to individual fragrance chemicals.
24520359 - Development and preliminary validation of chinese preschoolers' eating behavior questio...
16805419 - Risk of allergy to food proteins in topical medicinal agents and cosmetics.
24625409 - Risk analysis of sulfites used as food additives in china.
1176789 - The mode of growth of eccrine duct milia.
16864139 - Non-digestible oligosaccharides with prebiotic properties.
3096899 - Prophylactic treatment of childhood asthma.
23964049 - Novel psychoactive substances: a novel clinical challenge.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  31     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:    1997 Jul-Aug
Date Detail:
Created Date:  1997-09-18     Completed Date:  1997-09-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  919-21     Citation Subset:  IM    
Affiliation:
School of Pharmacy, West Virginia University, Morgantown 26506, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / adverse effects,  therapeutic use
Antitrichomonal Agents / therapeutic use
Clinical Trials, Phase III as Topic
Clostridium difficile*
Drug Therapy, Combination
Enterocolitis, Pseudomembranous / epidemiology,  microbiology*,  therapy*
Humans
Metronidazole / therapeutic use
Risk Factors
Saccharomyces
Vancomycin / therapeutic use
Yeast, Dried / therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antitrichomonal Agents; 1404-90-6/Vancomycin; 443-48-1/Metronidazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Guanfacine use in children with attention deficit hyperactivity disorder.
Next Document:  Arthroscopic repairs of triangular fibrocartilage complex tears.